prof. dr. E.G.E. (Elisabeth) de Vries

Professor

Research

  1. 2019
  2. 2018
  3. Adami, H-O., Berns, A., Celis, J. E., de Vries, E., Eggermont, A., Harris, A., ... Ringborg, U. (2018). European Academy of Cancer Sciences: Position paper. Molecular oncology, 12(11), 1829-1837. https://doi.org/10.1002/1878-0261.12379
  4. Jalving, M., & de Vries, E. G. E. (2018). Immune Checkpoint Blockade: Response Patterns and Assessment of Response. In J. B. A. G. Haanen , R. Califano, I. Lugowska, & M. C. Garassino (Eds.), ESMO Handbook of Immuno-Oncology (1 ed., pp. 258-266). (ESMO Handbook Series). the European Society for Medical Oncology (ESMO).
  5. Wolff-Holz, E., Garcia Burgos, J., Giuliani, R., Befrits, G., de Munter, J., Avedano, L., ... Tabernero, J. (2018). Preparing for the incoming wave of biosimilars in oncology. ESMO Open, 3(6), [e000420]. https://doi.org/10.1136/esmoopen-2018-000420
  6. 2017
  7. Cherny, N. I., Dafni, U., Bogaerts, J., Latino, N. J., Pentheroudakis, G., Douillard, J. -Y., ... de Vries, E. G. E. (2017). ESMO-Magnitude of Clinical Benefit Scale version 1.1. Annals of Oncology, 28(10), 2340-2366. https://doi.org/10.1093/annonc/mdx310
  8. Dafni, U., Karlis, D., Pedeli, X., Bogaerts, J., Pentheroudakis, G., Tabernero, J., ... Cherny, N. I. (2017). Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules. ESMO Open, 2(4), [000216]. https://doi.org/10.1136/esmoopen-2017-000216
Previous 1 2 3 4 5 6 7 8 ...19 Next

ID: 162081